统计剂使用与痴呆症之间的关联以及相关机制:从2007年到2023年的图书统计分析
Xian-Zheng Sang1, Wen Chen1, Xiao-Xiang Hou1
1Department of Neurosurgery, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Journal of Alzheimer's disease : JAD
|September 13, 2024
概括
类药物显示出对痴呆症治疗的潜力,但它们的认知效果尚不确定. 需要进一步的研究来澄清基甲基酸-共酶A (HMG-CoA) 减少酶抑制剂与痴呆症患者的认知功能之间的关联.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 图书统计学 图书统计学
背景情况:
- 新出现的证据表明,甲基甲基-协酶A (HMG-CoA,他类药物) 可能为痴呆症提供治疗益处.
- 由于潜在的副作用和不清楚的长期疗效,在痴呆症治疗中使用他类药物正在研究中.
研究的目的:
- 评估目前关于在痴呆症中使用他类药物的研究环境.
- 确定这一领域的关键研究问题和知识差距.
主要方法:
- 在痴呆症中使用他类药物的系统文献搜索 (2007-2023年) 使用Web of Science核心集合.
- 使用VOSviewer和CiteSpace进行图书计量分析,分析出版趋势,主要贡献者和有影响力的作品.
主要成果:
- 分析了来自58个国家的560篇文章,强调美国是领先的国家,梅奥诊所是关键机构.
- 通过关键词分析确定了著名的作者,阿尔茨海默病杂志作为领先的出版场所,以及关键研究主题.
- 观察到稳定的年度出版量与持续的引用增长,表明研究兴趣日益增加.
结论:
- 类药物为痴呆症提供了一个有希望但不确定的治疗途径,需要对其认知影响进行进一步的研究.
- 主要研究问题围绕着澄清他类药物使用与认知功能之间的关联,考虑多方面的潜在机制.
- 本文献计量分析提供了关于他类药物和痴呆症研究现状的全面概述.
相关概念视频
01:30Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
588
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
588
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
108
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
108